Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 12 - April 2021
  3. Longitudinal multi-omics analysis reveals subset-specific mechanisms underlying irritable bowel syndrome
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 12 - April 2021
  3. Longitudinal multi-omics analysis reveals subset-specific mechanisms underlying irritable bowel syndrome
Gastroenterology

Longitudinal multi-omics analysis reveals subset-specific mechanisms underlying irritable bowel syndrome

IBD

Commented articles

By Prof. Harry Sokol
Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

 Irritable bowel syndrome (IBS). Coloured X-ray of the sigmoid colon (far right to centre) and rectum (lower centre) of a patient suffering from IBS.

About this article

Created 12 August 2021
Updated 06 January 2022

Commentary on the original article by Mars et al. Cell 2020 [1]

The gut microbiome is implicated in numerous chronic gastro-int estinal disorders in humans. Determining its role however has been rendered difficult due to the lack of correlation between animal and human studies as well as that of an integrated multi-omics view of disease-specific physiological changes. The authors integrated longitudinal multi-omics data from the intestinal microbiome, the metabolome, the host epigenome and the transcriptome in the context of irritable bowel syndrome (IBS) host physiology. They have identified IBS sub-type specific and symptom-related variations in microbial composition and function. A sub-group of changes identified in microbial metabolites corre sponds to host physiological mechanisms which are relevant to IBS. By compiling multiple data layers, the authors identified purine metabolism to be a new host-micro biota metabolic pathway in IBS with potential for therapeutic application. This study highlights the value of longitudinal sampling and the integration of complementary multi-omics data in the identification of functional mechanisms which may be future therapeutic targets in a global treatment strategy for chronic intestinal diseases.

WHAT DO WE ALREADY KNOW ABOUT THIS SUBJECT?

Irritable bowel syndrome (IBS) is a disorder observed in patients all over the world, characterised by recurrent abdominal pain or discomfort. Occurring mainly in women, IBS is associated with changes in the form or frequency of stools and it is the form of the latter which defines the IBS subsets: IBS with constipation (IBS-C), IBS with diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M).

The pathogenesis of IBS involves changes in gastro-intestinal motility, intestinal secretion, visceral hypersensitivity and intestinal permeability, all of which can be modified by the gut microbiome [2]. Moreover, IBS symptoms are influenced by the diet, host genetics and the environment, which are also known to modulate the human gut microbiome [2]. Experimental evidence supporting the role of the gut microbiome in IBS are based on patient-to-gnotobiotic mouse transplantation studies which reproduced certain symptoms associated with IBS-C and IBS-D (transit time, sensation of pain, intestinal permeability…) [3]. However, in the absence of robust animal models of IBS, studies in humans are needed to determine the interactions between the gut microbiome and the pathological pathways specific to humans. Human IBS studies are limited in general by the use of transversal sampling and a failure to stratify into patient subsets, which is reflected in the lack of agreement in the results obtained in the large number of studies on the microbiome [4].

The well-described influence of gastro-intestinal transit on the intestinal microbiome increases the variability of the studies even more. In addition, IBS, in common with other chronic gastro-intestinal disorders, is characterised by periods of remission and flare up of the symptoms, and transversal sampling therefore fails to take into account the fluctuations of the disease over time. Lastly, the inherent differences in host physiology between humans and animals have been an obstacle to progress in our understanding of the mechanistic roles of the gut microbiome in IBS. The authors performed a longitudinal study in subsets of patients with IBS, integrating multi-omics measurements, including the microbial metagenome, host transcriptome and the methylome with assessment of host cell functions. This revealed mechanisms specific to the IBS subset induced by impaired microbial metabolism, which corresponded to simultaneous changes in the host physiology.

Key point

  • The functions of the gut microbiota are impaired in IBS and there are differences between IBS-C and IBS-D

  • The increase in the production of tryptamine and the reduction in transformation of bile acids may be implicated in IBS-D

  • Over-consumption of hypoxanthine by the microbiota and host cells may be implicated in IBS by altering the energy level of the intestinal mucosal epithelium cells.

Image

WHAT ARE THE MAIN INSIGHTS FROM THIS STUDY?

Here, the authors conducted a prospective observational longitudinal study with multi-omics analysis of the gut microbiome and the host cells. Healthy subjects were compared with patients with IBS-C and IBS-D. A total of 77 participants supplied at least one stool sample (a total of 474 stool samples were obtained), and 42 participants received a sigmoidoscopy which provided colon biopsies. In order to identify the microbial factors causing the symptoms specific to each of the IBS subsets, metagenomic sequencing and a metabolomic analysis were performed on the stool samples. A metabolomic analysis and cytokine assays were performed on serum samples. Lastly, 16S sequencing, and metabolomic, transcriptomic and methylomic analyses were performed on the colon biopsies. The authors identified differences in the composition and diversity of the gut microbiota between healthy subjects and IBS-C or IBS-D patients.

Metabolomic analysis of the stools revealed increased levels of tryptamine, a tryptophan metabolite produced by certain intestinal bacteria, in patients with IBS-D (Figure 1). Because tryptamine accelerates transit due to an action on the serotonin receptor, 5-HT4, it is suggested that it could have a role in the phenotype of these patients. Similarly, the proportion of primary bile acids was higher in patients with IBS-D, a sign of impaired transformation of bile acids by the microbiota. In vitro experiments suggest that primary bile acids increase secretion in the colon and could also participate in the phenotype.

Lastly, the integration of multi-omics data identified a potential new mechanism in IBS. The results suggest that in IBS patients there is increased degradation of purine nucleotides and of hypoxanthine in particular, by the microbiota and the host cells, which induces stress in the colon. It is suggested that this could lead to a compensatory response with an increase in purine recuperation. The low levels of purine nucleotides could lead to a reduced source of energy to the mucosal epithelium and to a reduced capacity for repair of the gut mucosa, which could partly contribute to IBS physiopathology.

WHAT ARE THE CONSEQUENCES IN PRACTICE?

These data suggest a role of the gut microbiota in the physiopathology of IBS with differences between IBS-C and IBS-D. Moreover, these results point towards the potential role of a deficiency in purine nucleotides, in particular via an over-consumption of hypoxanthine by the microbiota and the host cells. These results point the way to treatments stimulating the production of microbial hypoxanthine or inhibiting xanthine oxidase locally in the intestine.

Conclusion

This longitudinal study with integrated multi-omics shows the value of longitudinal studies in humans and highlights functional alterations to the microbiota in IBS which may potentially be implicated in the physiopathology of this disease. The new leads which have been identified may be new therapeutic targets.

Sources

1 Mars RAT, Yang Y, Ward T, et al. Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. Cell. 2020 Sep 17;182(6):1460-1473.e17.

2 Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol 2017 ; 312 : G52–G62.

3 Edogawa S, Edwinson AL, Peters SA, et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut 2020 ; 69 : 62-73.

4 Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome- a systematic review. Gastroenterology 2019 ; 157 : 97-108.

Tags
IBD Gut microbiota

en_view en_sources

    Focus
    Microbiota 12 - April 2021
    • Overview
      • Covid-19 & the gut microbiota
      • Crosstalk between the gut microbiota and the host's immune response to combat infections
    • Commented article
      • Longitudinal multi-omics analysis reveals subset-specific mechanisms underlying irritable bowel syndrome
      • Duodenal microbiota in stunted undernourished children with enteropathy
    • Congress Review
      • Microbiota highlights from ueg week virtual 2020
    • Press review
      • Gut Microbiota
      • Skin Microbiota
      • Vaginal Microbiota
    Created 12 August 2021
    Updated 06 January 2022

    About this article

    To know more about this topic.

    Main topic

    IBD

    Content type

    Commented article
    Crosstalk between the gut microbiota and the host's immune response to combat infections
    Duodenal microbiota in stunted undernourished children with enteropathy
    Focus

    Microbiota 12 - April 2021

    Overview

    Covid-19 & the gut microbiota Crosstalk between the gut microbiota and the host's immune response to combat infections

    Commented article

    Longitudinal multi-omics analysis reveals subset-specific mechanisms underlying irritable bowel syndrome Duodenal microbiota in stunted undernourished children with enteropathy

    Congress Review

    Microbiota highlights from ueg week virtual 2020

    Press review

    Gut Microbiota Skin Microbiota Vaginal Microbiota
    Gastroenterology
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo